BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 28390983)

  • 1. Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning Regimen.
    Dodero A; Patriarca F; Milone G; Sarina B; Miceli R; Iori A; Barretta F; Terruzzi E; Mussetti A; Pini M; Bosi A; Dominietto A; Cascavilla N; Onida F; Narni F; Farina L; Rambaldi A; Corradini P
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1102-1109. PubMed ID: 28390983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant.
    Khouri IF; Milton DR; Gulbis AM; Jabbour EJ; Nastoupil L; Ledesma C; Anderlini P; Bashir Q; Daher M; Im JS; Iyer SP; Marin D; Mehta RS; Olson AL; Popat UR; Qazilbash M; Saini N; Samaniego F; Rondon G; Medeiros LJ; Champlin RE
    Clin Cancer Res; 2021 Nov; 27(21):5847-5856. PubMed ID: 34380640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
    Massoud R; Naim H; Klyuchnikov E; Janson D; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2024 Feb; 112(2):276-285. PubMed ID: 37845834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Follow-Up of
    Puronen CE; Cassaday RD; Stevenson PA; Sandmaier BM; Flowers ME; Green DJ; Maloney DG; Storb RF; Press OW; Gopal AK
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2211-2215. PubMed ID: 30454872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Cabrero M; López-Corral L; Jarque I; de la Cruz-Vicente F; Pérez-López E; Valcárcel D; Sanz J; Espigado I; Ortí G; Martín-Calvo C; de la Serna J; Caballero D;
    Bone Marrow Transplant; 2024 Mar; 59(3):359-365. PubMed ID: 38167647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell transplantation for the management of follicular lymphoma.
    Hosing C
    Stem Cells Cloning; 2010 May; 3():69-80. PubMed ID: 24198512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial.
    Kühnl A; Cunningham D; Counsell N; Hawkes EA; Qian W; Smith P; Chadwick N; Lawrie A; Mouncey P; Jack A; Pocock C; Ardeshna KM; Radford J; McMillan A; Davies J; Turner D; Kruger A; Johnson PW; Gambell J; Rosenwald A; Ott G; Horn H; Ziepert M; Pfreundschuh M; Linch D
    Ann Oncol; 2017 Jul; 28(7):1540-1546. PubMed ID: 28398499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
    Patriarca F; Masciulli A; Bacigalupo A; Bregante S; Pavoni C; Finazzi MC; Bosi A; Russo D; Narni F; Messina G; Alessandrino EP; Carella AM; Milone G; Bruno B; Mammoliti S; Bruno B; Fanin R; Bonifazi F; Rambaldi A;
    Biol Blood Marrow Transplant; 2019 May; 25(5):932-940. PubMed ID: 30579966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
    N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
    Bakris GL; Agarwal R; Anker SD; Pitt B; Ruilope LM; Nowack C; Kolkhof P; Ferreira AC; Schloemer P; Filippatos G; ;
    Am J Nephrol; 2019; 50(5):333-344. PubMed ID: 31655812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    Perkovic V; Jardine MJ; Neal B; Bompoint S; Heerspink HJL; Charytan DM; Edwards R; Agarwal R; Bakris G; Bull S; Cannon CP; Capuano G; Chu PL; de Zeeuw D; Greene T; Levin A; Pollock C; Wheeler DC; Yavin Y; Zhang H; Zinman B; Meininger G; Brenner BM; Mahaffey KW;
    N Engl J Med; 2019 Jun; 380(24):2295-2306. PubMed ID: 30990260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
    Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
    N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 Feb; 397(10274):605-612. PubMed ID: 33545096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy.
    Chari A; Munder M; Weisel K; Jenner M; Bygrave C; Petrucci MT; Boccadoro M; Cavo M; van de Donk NWCJ; Turgut M; Demirkan F; Karadogan I; Libby E; Kleiman R; Kuppens S; Bandekar R; Neff T; Heuck C; Qi M; Clemens PL; Goldschmidt H
    Adv Ther; 2021 Feb; 38(2):1328-1341. PubMed ID: 33474705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
    N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
    ; Horby P; Mafham M; Linsell L; Bell JL; Staplin N; Emberson JR; Wiselka M; Ustianowski A; Elmahi E; Prudon B; Whitehouse T; Felton T; Williams J; Faccenda J; Underwood J; Baillie JK; Chappell LC; Faust SN; Jaki T; Jeffery K; Lim WS; Montgomery A; Rowan K; Tarning J; Watson JA; White NJ; Juszczak E; Haynes R; Landray MJ
    N Engl J Med; 2020 Nov; 383(21):2030-2040. PubMed ID: 33031652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexamethasone in Hospitalized Patients with Covid-19.
    ; Horby P; Lim WS; Emberson JR; Mafham M; Bell JL; Linsell L; Staplin N; Brightling C; Ustianowski A; Elmahi E; Prudon B; Green C; Felton T; Chadwick D; Rege K; Fegan C; Chappell LC; Faust SN; Jaki T; Jeffery K; Montgomery A; Rowan K; Juszczak E; Baillie JK; Haynes R; Landray MJ
    N Engl J Med; 2021 Feb; 384(8):693-704. PubMed ID: 32678530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
    Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
    Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.